A recent study suggests that VEGF levels may serve as a predictive biomarker for the identification of NSCLC patients who are likely to benefit from the inclusion of bevacizumab in their immunotherapy regimens [11]. Here, VEGFA is linked to non-small cell lung carcinoma.